• 14 June 2010
  • News
  • By

Consistent performer

Haffkine Bio-Pharma has witnessed a sustained growth in the last five years. It clocked an annual sales revenue of Rs 168.98 crore for the year 2009

19
Haffkine
Bio-Pharma

Head:
P R Sabde (MD)

Business:
Production and supply of biopharmaceutical products to state agencies/government organizations



Startup Year:
1975

Address:
Acharya Donde Marg, Parel, Mumbai - 400012

Tel:
+91-22-24129320

Fax:
+91-22-24168578

Website:
www.vaccinehaffkine.org
Haffkine Bio-Pharmaceutical Corporation (HBPCL), a fully-owned Government of Maharashtra has been engaged in the manufacture and supply of wide range of biological and non-biological products comprising bacterial and viral vaccines, antisera, toxoids injectables. It clocked an annual sales revenue of Rs 168.98 crore for the year 2009. Haffkine Bio-Pharma has witnessed a consistent growth in last five years.

Haffkine Bio-Pharma has been contributing significantly by supplying Oral Polio Vaccine to UNICEF and Government of India. Similarly, it ensures timely and adequate supply of its products at a reasonable price to all the health institutions/hospitals of Govt. of Maharashtra.

The company successfully obtained UN pre-qualification for Monovalent Oral Polio Vaccine Type1 in 2007 and since then there has been no look back for Haffkine Bio-Pharma. Recently it exported tOral Polio Vaccine (tOPV) to Yemen.

Haffkine Bio-Pharma, which has a capacity to manufacture 60 crore doses of OPV per year, achieved a sustained growth by entering into business alliances aimed at the manufacture of new vaccines of social relevance. In keeping with the corporate philosophy of continuous improvement the company has taken up modernization and up-gradation of pharmaceutical manufacturing facility at Parel. Similar up-gradation and modernization of Antisera facility at Pimpri is under progress which will be commissioned during this year.

Haffkine Bio-Pharma is also planning to undertake building new manufacturing facilities complying with WHO GMP standards for DTP/ Pentavalent Vaccine and the possibilities are being explored for technology transfer for pentavalent vaccine. Considering these modernization and up-gradation and expansion plans, it is poised for a bright outlook in areas like vaccines, antisera and pharmaceuticals.

Haffkine has a farm and laboratory at Pimpri near Pune where antitoxins and sera for snake and scorpion venom, tetanus and diphtheria toxins are produced. It also formulates pharmaceutical products, disinfectants, ointments, injectables, syrups and mixtures at its unit at Mumbai. It has a well-equipped animal house in Mumbai for breeding laboratory animals.

When HINI influenza virus started creating problems by spreading across the world in 2009, the scientists at the Haffkine Institute which was earlier part of Haffkine Bio-Pharma discovered an ominous new flu virus, sparking-off fears of a catastrophic global outbreak. Haffkine Institute doubled its novel H1N1 influenza (swine flu) testing capacity by procuring new equipment. At present, it has the capacity to test approximately 80 samples per day. This apart specific initiatives have been taken for meeting the demand for the life saving drugs in other states, as well as in other countries.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X